Reproducibility & Per-Approval Savings

Platform-driven reproducibility improvements from 45% (status quo) to 85% unlock substantial cost savings by reducing false-positive programs entering clinical trials.

Status Quo Reproducibility

45%

Current baseline preclinical signal quality

Platform Reproducibility

85%

Achievable with Protocol‑Plus

Per-Approval Savings

~$391M

At 85% reproducibility vs baseline

Savings per Approval vs Baseline

Status Quo

45% reproducibility

Platform

~$391M

85% reproducibility

Max potential at 90%: ~$440M

Composition of ~$391M Savings

Fewer false-positive programs entering clinic

~$350M

Reduced admin/operational overhead

~$25M

Reduced reagent/consumable waste

~$16M

Total: ~$391M

Key Insight

At 85% reproducibility, approximately 89% of total per-approval savings are explained by fewer false-positive programs entering the clinic. Operational efficiencies and reagent waste reduction are valuable, but secondary compared to the dominant impact of improved preclinical signal quality.

Critical Finding

Preclinical signal quality is the dominant cost driver.